Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.


$1,230 in Instant Income?

$1,230 in Instant Income?Our top income expert recently pulled the wraps off his breakthrough moneymaking technique. And he proved beyond a shadow of a doubt how you can use it to generate instant cash payouts of up to $1,230 (or more). Over and over again. But then he took things a big step further and guaranteed you can make $1 million by following his program. And the second he did, our phones went nuts! Space is limited — get the details here.



Can This “Bad Boy” Tech Billionaire Eradicate Cancer?

By John Persinos on April 25, 2016

Sean Parker, the “bad boy” of Silicon Valley, just promised $250 million of his own money to fight cancer. The ramifications for investors are huge.

The multi-billionaire co-founder of Napster and former president of Facebook will donate $250 million, which is about 10% of his estimated net worth of $3 billion, towards the creation of the Parker Institute for Cancer Immunotherapy. The institute will focus on the development of breakthrough immune therapies to fight cancer cells.

Parker’s new philanthropic venture is a 180-degree spin from his past endeavors. The roguish tech genius with a penchant for throwing elaborate parties has decided to focus his entrepreneurial efforts and money not on file sharing services or social media but medical science.

Research surrounding immunotherapy is a hot scientific area, as scientists and physicians try to find a way to get the body to fight cancer by itself, eliminating the need for costly and painful techniques such as chemotherapy and radiation. As we’ve been sharing recently, the winners in the immunotherapy space will prove superb long-term investments.

Parker has already brought on board six cancer centers: Memorial Sloan Kettering, Stanford Medicine, the University of California in Los Angeles, the University of California in San Francisco, the University of Pennsylvania, and the University of Texas MD Anderson Cancer Center.

Collectively, these prestigious centers will spearhead the research. Through its association with them, Parker’s institute plans to serve as the link between academic research and the biopharmaceutical industry.

The institute also will work on clinical trials and patents together with the industry. Consequently, companies that test a new drug won’t have to wait for months to amass patients at a single location and can instead enjoy ready access to patients across these six locations with minimum regulatory delays.

This new model for creating and testing drugs will allow the sharing of patents among institutions, which will accelerate the speed of innovation. Parker’s institute also paves the way for directing revenue back to research, in the event that any of the patents turn into successful drugs.

The upshot: With these developments in the works, certain biotech firms in the field of immunotherapy are poised for a new wave of growth.

In fact, we’ve already found one fast-growing company that’s making enormous strides in immunotherapy. Parker’s institute should kick-start immunotherapy growth in general and the prospects of this company in particular. To learn more about this amazing story, click here.

You might also enjoy…


R.I.P Bull Market—Here’s How To Protect Your Wealth

I hope you’ve enjoyed the phenomenal bull market of the past eight years…

Because it’s about to come to a screeching halt.

The Federal Reserve’s nearly decade-long spending spree has finally come to an end.

With no other options left at their disposal, the Fed has no other choice than to raise interest rates to keep inflation in check.

And that leaves you with two options…

Do nothing and suffer the agony of watching the profits you’ve accumulated over the years evaporate right before your eyes…

Or reposition your portfolio and invest in companies which prosper as inflation rises and interest rates soar.

I think the choice is clear. And I’ll show you the best new positions you can take if you click here.

Stock Talk — Post a comment Comment Guidelines

Our Stock Talk section is reserved for productive dialogue pertaining to the content and portfolio recommendations of this service. We reserve the right to remove any comments we feel do not benefit other readers. If you have a general investment comment not related to this article, please post to our Stock Talk page. If you have a personal question about your subscription or need technical help, please contact our customer service team. And if you have any success stories to share with our analysts, they’re always happy to hear them. Note that we may use your kind words in our promotional materials. Thank you.

You must be logged in to post to Stock Talk OR create an account.

Create a new Investing Daily account

  • - OR -

* Investing Daily will use any information you provide in a manner consistent with our Privacy Policy. Your email address is used for account verification and will remain private.